Format

Send to

Choose Destination
Int J Hematol. 2017 Jan;105(1):7-16. doi: 10.1007/s12185-016-2118-8. Epub 2016 Oct 31.

SET/MLL family proteins in hematopoiesis and leukemia.

Author information

1
Department of Pediatrics and Pharmacology, University of Colorado, Denver/Anschutz Medical Campus, Aurora, CO, 80045, USA.
2
Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 03755, USA.
3
Department of Pediatrics and Pharmacology, University of Colorado, Denver/Anschutz Medical Campus, Aurora, CO, 80045, USA. patricia.ernst@ucdenver.edu.

Abstract

Accumulating recent evidence supports the notion that many enzymes that modify histones are fundamental players in normal hematopoiesis as well as hematologic malignancies, and represent an important new class of drug targets. Histone H3 lysine 4 (H3K4) methylation plays several distinct roles in gene expression and is modulated by specific methyltransferases and demethylases. Recent progress has been made clarifying the unique biological roles of the enzymes that carry out H3K4 methylation, yet a detailed understanding of H3K4 methylation states in various genomic contexts and the diverse functions of the enzymes that perform these methylation events is incomplete, but developing rapidly. In this review, we summarize and discuss the general mechanisms of H3K4 methylation, and how the six main enzymes from the SET/MLL family (responsible for H3K4me1/me2/me3) function in hematopoiesis and in hematologic malignancies.

KEYWORDS:

AML; H3K4 methylation; Histone methyltransferase; Leukemia; MLL1; MLL2; Wbp7

PMID:
27796741
DOI:
10.1007/s12185-016-2118-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center